-

Bruker to Host Virtual Investor Day on June 17th, 2021

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) will host a Virtual Investor Day on June 17th, 2021, starting at 10:00 AM Eastern Daylight Time. The Investor Day will be in a virtual format, with no option to attend in person.

Bruker’s Virtual Investor Day will provide a deeper look into the Company’s strategies and Project Accelerate 2.0 initiatives and will feature presentations by the Executive Leadership Team, followed by a live Q&A session. Bruker also intends to communicate its outlook for medium-term financial performance at the event.

The Virtual Investor Day will be broadcast live, beginning at 10:00 am EDT, and concluding at 1:00 pm EDT. A link to the Investor Day will be available in the Events & Presentations section of the Company’s Investor Relations website at https://ir.bruker.com. It can also be accessed at https://investorrelations.bruker.com/2021/begin. All investors and analysts are requested to register in advance of the event. A replay will be available on Bruker’s Investor Relations web site after the Investor Day.

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.

Contacts

Miroslava Minkova
Senior Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

Industry:

Bruker Corporation

NASDAQ:BRKR
Release Versions
English

Contacts

Miroslava Minkova
Senior Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 663 – 3660, ext. 1479
E: Investor.Relations@bruker.com

More News From Bruker Corporation

Bruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced the launch of CellScape™ XR, a next-generation spatial proteomics platform designed to advance the development of diagnostic and prognostic assays by delivering unprecedented quantitative performance, robustness, and flexibility. CellScape XR addresses a critical bottleneck in translational research by enabling high-throughput, reproducible spatial proteomics at a scale and rigor required for translational and clinical...

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications. “Noet...

Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities,...
Back to Newsroom